ResMed Inc. Company Profile

22:20 EDT 22nd March 2019 | BioPortfolio

ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries.

News Articles [57 Associated News Articles listed on BioPortfolio]

ResMed’s top-of-head CPAP mask now available across US

The top-of-head connection keeps tubing out of the wearer’s way, letting them move and sleep in any position. The nasal cradle cushion – ResMed’s first – is designed The post ResMed’s top-o...

ResMed to Acquire Propeller Health for $225M, Will Operate as Standalone Business

ResMed to acquire digital therapeutics maker Propeller Health for $225 million, establishing itself as a leader in COPD management. ResMed, a provider of cloud-connected medical devices and out-of-hos...

ResMed To Add To Software Offerings With $750M MatrixCare Acquisition

Medical device maker ResMed has agreed to acquire Minnesota-based MatrixCare, which makes software for long-term care providers, for $750 million. San Diego’s ResMed (NYSE: ticker[[RMD]]) announced ...

ResMed completes acquisition of HB Healthcare

HBH, a fast-growing privately owned South Korean home medical equipment provider, serves both reimbursed and cash-pay customers of sleep and respiratory care devices. ResMed intends to reach millions ...

ResMed completes $750M acquisition of MatrixCare

ResMed has announced the completion of its $750 million buy of post-acute-care software maker MatrixCare, which will operate  -More- 

ResMed Boosts Connected Health Play With $225M Propeller Health Deal

ResMed has inked a $225 million deal to acquire Propeller Health, in the latest endorsement of Internet-connected devices for healthcare. The acquisition, which is expected to close by the end of Marc...

ResMed buys Propeller Health for $225M to enhance focus on COPD

Digital therapeutics company Propeller will continue to operate as a standalone business within ResMed’s Respiratory Care portfolio.

ResMed to buy digital therapeutics firm Propeller Health for $225m

Based in Madison of Wisconsin, Propeller Health offers connected health solutions for people with chronic obstructive pulmonary disease (COPD) and asthma. ResMed CEO Mick Farrell said: “Acquiring Pr...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [6 Associated Clinical Trials listed on BioPortfolio]

Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.

Prospective, observational cohort study to investigate the prevalence of sleepiness and sleep-related breathing disorders in patients with Fabry disease (FD). For this, an Epworth Sleepine...

Evaluation of the Role of Nocturnal Non-Invasive Ventilation in Pulmonary Rehabilitation

Hypothesis: Hospital based, comprehensive pulmonary rehabilitation of patients with COPD in GOLD stage IV can be optimized by application of nocturnal non invasive ventilation. This hypot...

Non-Invasive Ventilation in Patients With Severe Chronic Obstructive Pulmonary Disease and Lung Emphysema (COPD)

Non-invasive ventilation is frequently applied in patients with acute exacerbation of COPD, but no evidence exists about the effect of long term application/home application. This study t...

COPD Exacerbations

Detecting exacerbations to prevent a severe and / or to early treat an exacerbation is crucial in patients with COPD in order to prevent hospitalization. Patients with invasive mechanical ...

Benefit of Cheyne-Stokes Respiration Remote Monitoring in CPAP-treated Patients With Obstructive Sleep Apnea to Detect Early Events of Heart Failure.

Obstructive sleep apnea (OSA) syndrome affects 40-60% of patients presenting with cardiovascular diseases. Cheyne-Stokes respiration is a type of central apnea characterised by the presenc...

Companies [6 Associated Companies listed on BioPortfolio]


ResMed (NYSE: RMD and ASX: RMD.AX) is a leading developer, manufacturer and marketer of products for the screening, treatment and long-term management of sleep-disordered breathing (SDB) and other res...

ResMed, Inc.

ResMed is a leading developer, manufacturer and distributor of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. The company is dedicat...

ResMed Inc.

ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with ev...

SleepScore Labs

SleepScore Labs™ advances the science and technologies around sleep and overall health. Together with the foremost medical, health, and scientific experts from around ...

Dehaier Medical Systems Ltd.

Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company...

More Information about "ResMed Inc." on BioPortfolio

We have published hundreds of ResMed Inc. news stories on BioPortfolio along with dozens of ResMed Inc. Clinical Trials and PubMed Articles about ResMed Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ResMed Inc. Companies in our database. You can also find out about relevant ResMed Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record